• GIVLAARI is a prescription medicine used to treat AHP in adults. There are 4 types of AHP:
  • Acute intermittent porphyria (AIP)
  • Variegate porphyria (VP)
  • Hereditary coproporphyria (HCP)
  • ALAD-deficiency porphyria (ADP)
• Most patients in GIVLAARI clinical studies had AIP, the most common type of AHP

GIVLAARI is given once a month as a subcutaneous injection (under the skin) by a healthcare professional.

GIVLAARI can cause injection site reactions.

Tell your doctor or nurse right away if you experience any of the following symptoms of an injection site reaction during treatment: redness, pain, itchiness, rash, discoloration, or swelling around the injection site.

If you miss a dose, talk to your doctor about scheduling your next dose as soon as possible.

GIVLAARI can cause liver problems. Your doctor will check your liver function by doing blood tests:

• Before you start using GIVLAARI
• Once a month for the first 6 months of treatment
• And when they think it is needed

If these tests show abnormal results, your healthcare provider will decide whether to temporarily interrupt or stop treatment with GIVLAARI.

GIVLAARI can cause kidney problems. Your doctor will check how your kidneys are working while you are using GIVLAARI.

GIVLAARI may cause increased levels of homocysteine (a type of amino acid ) in your blood. Your doctor will check your homocysteine levels before and during treatment by doing blood tests.

In clinical studies of GIVLAARI, some people on GIVLAARI used hemin to treat AHP attacks. Use of GIVLAARI with regularly scheduled (prophylactic) hemin was not studied in clinical trials of GIVLAARI. Talk to your doctor if you have questions about your treatment plan.

GIVLAARI has not been studied in women who are pregnant. If you are pregnant or plan to become pregnant, it is important to discuss your treatment plan with your doctor.

Keeping a journal to track how you feel is a great way to see if there is progress over time. You can compare your notes from month to month to see any potential changes in your health.

Be sure to bring your journal with you to doctor appointments to remember any questions or share your experience.

Yes, GIVLAARI was studied in a 6-month study with a 30-month extension for a total of 36 months.

See the results through 36 months

GIVLAARI is given as an injection under the skin (subcutaneous) by a healthcare professional. Depending on your doctor’s recommendations and your insurance plan, home administration by a nurse or other healthcare professional may be an option.

GIVLAARI can cause a severe allergic reaction.

Tell your doctor or nurse right away if you experience any of the following signs or symptoms during treatment:

• Swelling – mainly of the lips, tongue or throat which makes it difficult to swallow or breathe
• Breathing problems or wheezing
• Feeling dizzy or fainting
• Rash or hives
• Itching

If you have a severe allergic reaction, your doctor or nurse will stop GIVLAARI treatment right away and you may need to take other medicines to control the symptoms.

After you and your doctor decide to begin GIVLAARI and enroll in our patient support program, Alnylam Assist™, we can provide support in 3 key areas: understanding benefits, eligibility for financial assistance, and disease and product education.

See how Alnylam Assist™ works